Viking Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€0.00 - Cost of goods sold
€74.21K - Gross profit
-€74.21K - SG&A expenses
€49.06M - R&D expenses
€132.48M - EBITDA
-€181.45M - D&A
€168.03K - EBIT
-€181.54M - Interest expenses
€40.94K - EBT
-€146.32M - Tax expenses
€0.00 - Net income
-€146.32M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€14.22M - Changes in working capital
€1.21M - Operating cash flow
-€130.10M - Capex
€0.00 - Other investing cash flow
€391.83M - Net investing cash flow
€117.91M - Total cash dividends paid
€0.00 - Issuance of common stock
-€37.65M - Debt repayment
€0.00 - Other financing cash flow
€41.38M - Net financing cash flow
€3.73M - Foreign exchange effects
-€97.24K - Net change in cash
-€8.56M - Cash at end of period
€28.90M - Free cash flow
-€130.10M
Balance sheet
- Cash and cash equivalents
€28.90M - Cash and short-term investments
€28.90M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€676.51M - Total current assets
€705.41M - Property, plant & equipment
€665.30K - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€0.00 - Other non-current assets
€46.06K - Total non-current assets
€711.36K - Total assets
€706.12M - Accounts payable
€4.69M - Short-term debt
€399.18K - Other current liabilities
€22.19M - Total current liabilities
€27.28M - Long-term debt
€349.71K - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€349.71K - Total liabilities
€27.63M - Common stock
€852.95 - Retained earnings
-€511.00M - Other equity
-€141.59K - Total equity
€678.49M - Total liabilities and shareholders' equity
€706.12M
Company information
- Market capitalization
€2.54B - Employees
45 - Enterprise Value
€3.21B
Company ratios
- Gross margin
-
0.0% - EBITDA margin
-
0.0% - EBIT margin
-
0.0% - EBT margin
-
0.0% - Net margin
-
0.0% - ROE
-
-21.6% Much better than peer group: -406.5% - ROA
-
-20.7% Much better than peer group: -280.9% - Asset turnover
-
0.0% - FCF margin
-
0.0% - FCF yield
-5.1% - Efficiency ratio
0.0% - Net sales per employee
-
€0.00 - Net income per employee
-
-€3.25M